9 results about "Mast cell stabilizer" patented technology

A collagen-boosting supplement that contains at least 4, optionally at least 10, collagen building block amino acids and is substantially free of histidine. The building block amino acids may be selected from: Glycine, L-Proline, L-Hydroxyproline, L-Glutamic Acid, L-Alanine, L-Arginine, L-Aspartic Acid, L-Serine, L-Leucine, L-Lysine, L-Hydroxylysine, L-Valine, L-Phenylalanine, L-Threonine, L-Isoleucine, L-Methionine, and L-Tyrosine. The supplement may further comprise: vitamin C; one or more mast cell stabilisers which may be selected from: quercetin, molybdenum, bromelain, DAO (diamine oxidase), Urtica Dioica (stinging nettle), Nigella Sativa (black cumin), Zingiber (ginger), Scutellaria baicalensis (Chinese skullcap), Sambucus (Elderberry), Aloe Vera, Syzygium aromaticum (clove), and matcha; one or more collagen-strengthening herbs which may be selected from: Bilberry, Centella, and Astragulus; one or more Glucosaminoglycans (GAGs) which may be selected from: Hyaluronic acid, glucosamine, and chondroitin; one or more antioxidants which may be selected from: astaxanthin and resveratrol; and / or one or more cofactors which may be selected from: zinc, biotin, silicon, manganese, magnesium, Vitamin D, Vitamin A, Vitamin E, and iron. The supplement may be a foodstuff, medicament, nutraceutical, or cosmetic. The supplement may be used to treat hypermobile Ehlers-Danlos syndrome (hEDS) while reducing the likelihood of mast cell degranulation through histamine activation.

The present invention relates to methods for treating chronic inflammatory conditions using a mast cell stabilizing compound. The invention further relates to compositions and dosage forms comprising mast cell stabilizing agents.

The present disclosure provides methods of treatment of neurodegenerative disease, such as a motor neuron disease, in subjects in need thereof. A therapeutically effective dose of a suitable mast cell stabilizer may be administered to suitable subjects, wherein the suitability of a subject is determined by the rate of progression of the disease over time or by the severity of the disease. A therapeutically effective dose of a suitable mast cell stabilizer may be administered to suitable subjects, wherein the suitability of a subject is determined by subject genotype and / or family genotypes or medical history. In certain embodiments, the therapy may comprise a cromolyn homolog salt, and suitable subjects are persons with amyotrophic lateral sclerosis (ALS). In certain embodiments, the subjects are patients with slow progressing ALS and / or the subjects have mild to moderate ALS. In certain embodiments, the subjects are persons with sporadic ALS or persons without familial ALS.

The invention discloses application of a mast cell inhibitor in prevention and treatment of brain injury after hair growth matrix bleeding, and relates to the technical field of biological medicines. The mast cell inhibitor is a mast cell stabilizer and plays a role by inhibiting degranulation of mast cells; the mast cell stabilizer is sodium cromoglycate or pharmaceutically acceptable salt, ester, solvate or prodrug thereof; the medicine is used for preventing and / or treating brain injury after newborn hair growth matrix bleeding, wherein the brain injury comprises one or more of neuroinflammation, lymphatic system dysfunction, intracerebral toxic metabolite accumulation, hematoma enlargement and neurobehavioral function impairment. Early activation of mast cells is used as a key intervention target spot for preventing and treating the brain injury after the newborn hair growth matrix bleeding; different from a traditional method for bleeding or wide later-stage inflammation, the method focuses on the extremely early hub link of the injury cascade reaction, and a novel prophylactic or ultra-early therapeutic thought is provided.

The present disclosure provides methods of treating a neurodegenerative disease in a subject in need thereof. A therapeutically effective dose of a combination of a suitable mast cell stabilizer and an NSAID may be administered to a suitable subject, wherein the suitability of the subject is determined by the subject genotype. In certain embodiments, the combination therapy may comprise a combination of a cromoglycin homolog salt and an NSAID, and a suitable subject is a person that is not a carrier of an APOE [epsilon] 4 variant of the APOE gene.

The disclosure demonstrates the role of mast cell stabilizers in treating rosacea. The disclosure also shows the role of mast cells, cathelicidin, serine protease and / or vitamin D3 in rosacea pathology and the use of antagonists and inhibitors thereof to treat rosacea.

The present disclosure provides compositions, uses thereof, and methods for treating subjects with obesity and / or metabolic disorders. In aspects and embodiments, the method comprises administering an effective amount of one or more of a mast cell stabilizer and an H1-antihistamine, in combination with a non-steroidal anti-inflammatory drug (NSAID), either in the same or separate compositions.

This disclosure provides a method for treating neurodegenerative diseases in subjects requiring treatment for neurodegenerative diseases. A therapeutically effective dose of a suitable combination of a mast cell stabilizer and an NSAID may be administered to a suitable subject, where the subject's eligibility is determined by the subject's genotype. In certain embodiments, the combination therapy comprises a combination of a cromolyn homologous salt and an NSAID, and the suitable subject is not a carrier of the APOE ε4 variant of the APOE gene.

The present invention aims to provide a method for preventing and treating myopia and a composition for use therein. [Solution] The present invention provides a method and composition for suppressing, improving, or treating myopia by administering choroidal resident immune cell function modifiers such as M2 macrophage polarization inducers, mast cell stabilizers, and chemical mediator release inhibitors, or lactic acid bacteria. Inducing polarization of M2 macrophages in the choroid, or regulating the function of choroidal resident immune cells by administering mast cell stabilizers, chemical mediator release inhibitors, or lactic acid bacteria, is effective in preventing and treating myopia.